Axogen Overview

  • Founded
  • 2002

Founded
  • Status
  • Public

  • Employees
  • 451

Employees
  • Stock Symbol
  • AXGN

Stock Symbol
  • Investments
  • 1

  • Share Price
  • $12.29

  • (As of Tuesday Closing)

Axogen General Information

Description

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically proven and economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, United Kingdom, Spain, South Korea, and several other countries.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Other Healthcare Services
Stock Exchange
NAS
Primary Office
  • 13631 Progress Boulevard
  • Suite 400
  • Alachua, FL 32615
  • United States
+1 (888) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Axogen Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$12.29 $12.11 $6.87 - $16.02 $520M 42.3M 213K -$0.75

Axogen Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 344,395 366,905 676,858 609,801
Revenue 128,202 127,358 112,300 106,712
EBITDA (26,004) (20,888) (19,272) (26,218)
Net Income (31,642) (26,985) (23,786) (29,135)
Total Assets 196,084 208,024 201,381 154,643
Total Debt 67,680 67,453 53,764 3,331
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Axogen Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Axogen‘s full profile, request access.

Request a free trial

Axogen Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regenerati
Biotechnology
Alachua, FL
451 As of 2021
000.00
00000000 000.00

000000

aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea co
0000000000000
Galway, Ireland
00 As of 0000
00.00
0000000 0000 00.00
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Axogen Competitors (1)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
000000 00000000000 Private Equity-Backed Galway, Ireland 00 00.00 0000000 0000 00.00
You’re viewing 1 of 1 competitors. Get the full list »

Axogen Patents

Axogen Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220280573-A1 Human umbilical cord-derived compositions and uses thereof for treating neuropathy Pending 03-Mar-2021 000000000
US-20220142150-A1 Packaging system for a medical product Pending 10-Nov-2020 0000000000
US-20220125995-A1 Fasciculated nerve grafts, methods of making the same, and methods of treatment using the same Pending 22-Oct-2020 00000000000
US-20220125044-A1 Packaging for wet tissue storage Pending 22-Oct-2020 0000000000
US-20220062505-A1 Nerve grafts and methods of preparation thereof Pending 28-Aug-2020 A61L27/3675
To view Axogen’s complete patent history, request access »

Axogen Executive Team (16)

Name Title Board Seat Contact Info
Karen Zaderej Chief Executive Officer & Chairman
Peter Mariani Executive Vice President and Chief Financial Officer, Finance
Isabelle Billet Executive & Chief Strategy Officer, Strategy
Bradley Ottinger General Counsel, Legal & Chief Compliance Officer, Legal
Angelo Scopelianos Executive
You’re viewing 5 of 16 executive team members. Get the full list »

Axogen Board Members (18)

Name Representing Role Since
Alan Levine Axogen Board Member 000 0000
Amy Wendell Axogen Board Member 000 0000
Gregory Freitag JD Axogen Board Member 000 0000
Guido Neels EW Healthcare Partners Board Member 000 0000
Karen Zaderej Axogen Chief Executive Officer & Chairman 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Axogen Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Axogen Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Axogen‘s full profile, request access.

Request a free trial

Axogen Acquisitions (1)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000000 30-Sep-2011 0000000000 0000 Drug Delivery 00000 000
To view Axogen’s complete acquisitions history, request access »

Axogen Subsidiaries (1)

Company Name Industry Location Founded
000000 Drug Delivery Texarkana, TX 0000
To view Axogen’s complete subsidiaries history, request access »